drugset / Trial / NCT00107393
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
Open-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer.
Timeline
- Start
- 2003-06
- Primary completion
- 2008-05
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1657 mg/m2 | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |